ARTAL GROUP S A
Q1 2023 Form 13-F
LUXEMBOURG
CIK 0001053906
· Institutional investment manager
Consolidated report · includes
5 managers
since Q2 2013
$1.7B Reported Value Total
Reported value
$1.7B
Quarter over quarter
-1.0%
Holdings
118
Top-10 concentration
48.3%
Reports holdings for
- Artal International S C A · File #028-15033 · since Q2 2013
- Westend S A · File #028-15029 · since Q2 2013
- Stichting Administratiekantoor Westend · File #028-15028 · since Q2 2013
- Artal International Management S A · File #028-15031 · since Q2 2013
- Artal Participations S.a r.l. (not a 13F filer in our records) · File #028-25146 · since Q4 2024
- Invus Public Equities Advisors LLC · File #028-11522 · Q2 2013 – Q2 2024
- Artal Luxembourg S A · File #028-19506 · Q1 2019 – Q1 2023
- Artal Treasury Ltd (not a 13F filer in our records) · File #028-19088 · Q4 2018 – Q4 2021
- Invus Advisors, L.L.C. (not a 13F filer in our records) · File #028-14596 · Q2 2013 – Q3 2013
Key People
Named on the latest Form 13-F filing — not necessarily an owner
Anne Goffard
Authorized Person
Filing Navigation
Coverage begins with the second quarter of 2013. Earlier quarters are not shown while their accuracy is being verified.
13F Metrics
Loading 13F Metrics
Q1 2023 13F record
Q1 2023 13F filing summary
| Period of report | March 31, 2023 |
|---|---|
| Filed | May 12, 2023 |
| Form | 13F-HR |
| Reported value | $1.7B |
| Positions | 118 |
| Change in reported value | -6.1% |
| New positions | 27 |
| Exited positions | 34 |
| Position turnover | 40.1% |
| Top-10 concentration | 48.3% |
13F filings by quarter
| Quarter | Positions | Value |
|---|---|---|
|
Q2 2026 13F
Filed Aug 13, 2026
|
2 | $931.1M |
|
Q1 2026 13F
Filed May 14, 2026
|
2 | $1.0B |
|
Q4 2025 13F
Filed Feb 12, 2026
|
2 | $714.6M |
|
Q3 2025 13F
Filed Nov 12, 2025
|
2 | $758.2M |
|
Q2 2025 13F
Filed Aug 13, 2025
|
2 | $930.2M |
|
Q1 2025 13F
Filed May 14, 2025
|
2 | $884.2M |
|
Q4 2024 13F
Filed Feb 14, 2025
|
2 | $1.2B |
|
Q3 2024 13F
Filed Nov 13, 2024
|
2 | $2.4B |
|
Q2 2024 13F
Filed Aug 14, 2024
|
109 | $3.9B |
|
Q1 2024 13F
Filed May 13, 2024
|
107 | $3.9B |
|
Q4 2023 13F
Filed Feb 9, 2024
|
91 | $3.0B |
|
Q3 2023 13F
Filed Nov 13, 2023
|
101 | $2.3B |
|
Q2 2023 13F
Filed Aug 11, 2023
|
114 | $3.2B |
|
Q1 2023 13F
Filed May 12, 2023
|
118 | $1.7B |
|
Q4 2022 13F
Filed Feb 13, 2023
|
125 | $1.8B |
|
Q3 2022 13F
Filed Nov 14, 2022
|
130 | $2.3B |
|
Q2 2022 13F
Filed Aug 11, 2022
|
132 | $1.9B |
|
Q1 2022 13F
Filed May 12, 2022
|
135 | $2.4B |
|
Q4 2021 13F
Filed Feb 11, 2022
|
144 | $3.7B |
|
Q3 2021 13F
Filed Nov 12, 2021
|
140 | $4.5B |
33 earlier quarters on file — choose one from the quarter menu above.
Top 20 holdings · Q1 2023
| # | Holding | Reported value | % of portfolio |
|---|---|---|---|
| 1 | LXRX LEXICON PHARMACEUTICALS INC | $218.2M | 12.96% |
| 2 | ONC BEIGENE LTD | $108.1M | 6.42% |
| 3 | APLS APELLIS PHARMACEUTICALS INC | $80.2M | 4.77% |
| 4 | SRRK SCHOLAR ROCK HLDG CORP | $72.2M | 4.29% |
| 5 | MORF MORPHIC HLDG INC | $68.3M | 4.06% |
| 6 | WGHTQ WW INTL INC | $61.1M | 3.63% |
| 7 | MRTX MIRATI THERAPEUTICS INC | $57.2M | 3.4% |
| 8 | KYMR KYMERA THERAPEUTICS INC | $53.5M | 3.18% |
| 9 | CYTK CYTOKINETICS INC | $48.1M | 2.86% |
| 10 | SWTX SPRINGWORKS THERAPEUTICS INC | $46.8M | 2.78% |
| 11 | CERE CEREVEL THERAPEUTICS HLDNG I | $46.7M | 2.77% |
| 12 | RVMD REVOLUTION MEDICINES INC | $44.9M | 2.67% |
| 13 | FOLD AMICUS THERAPEUTICS INC | $39.1M | 2.32% |
| 14 | IGMS IGM BIOSCIENCES INC | $34.5M | 2.05% |
| 15 | KRYS KRYSTAL BIOTECH INC | $33.0M | 1.96% |
| 16 | SAGE SAGE THERAPEUTICS INC | $31.5M | 1.87% |
| 17 | RLAY RELAY THERAPEUTICS INC | $27.6M | 1.64% |
| 18 | SE SEA LTD | $26.2M | 1.56% |
| 19 | AGEN AGENUS INC | $23.8M | 1.41% |
| 20 | ALVR ALLOVIR INC | $22.0M | 1.31% |
Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.